New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!

Morana Jovan-Embiricos net worth and biography

Morana Jovan-Embiricos Biography and Net Worth

Director of AlloVir

In 2003, Dr. Jovan co-founded F2 Ventures, a biotech venture capital platform and has since served as its Managing Partner. Prior to joining F2 Ventures, Dr. Jovan was a partner at MPM Capital. Dr. Jovan currently serves on the boards of directors of Damon Runyon Cancer Center Research Foundation, TriNetX, Inc. and Cullinan Oncology. Dr. Jovan received her Ph.D. in biophysical chemistry from the University of Cambridge and was a post-doctoral fellow at Harvard University.

How do I contact Morana Jovan-Embiricos?: The corporate mailing address for Dr. Jovan-Embiricos and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at [email protected]. Learn More on Morana Jovan-Embiricos' contact information.
Has Morana Jovan-Embiricos been buying or selling shares of AlloVir?: Morana Jovan-Embiricos has not been actively trading shares of AlloVir within the last three months. Most recently, Morana Jovan-Embiricos sold 3,815 shares of the business's stock in a transaction on Tuesday, November 9th. The shares were sold at an average price of $24.79, for a transaction totalling $94,573.85. Learn More on Morana Jovan-Embiricos' trading history.
Who are AlloVir's active insiders?: AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.
Are insiders buying or selling shares of AlloVir?: In the last year, insiders at the sold shares 53 times. They sold a total of 211,951 shares worth more than $149,284.16. The most recent insider tranaction occured on November, 19th when CAO Brett R Hagen sold 554 shares worth more than $304.70. Insiders at AlloVir own 33.8% of the company. Learn More about insider trades at AlloVir.
Information on this page was last updated on 11/19/2024.

Morana Jovan-Embiricos Insider Trading History at AlloVir

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
11/9/2021	Sell	3,815	$24.79	$94,573.85
11/5/2021	Sell	8,381	$24.80	$207,848.80
10/27/2021	Sell	2,200	$24.78	$54,516.00
10/25/2021	Sell	7,769	$24.82	$192,826.58
10/21/2021	Sell	100	$24.75	$2,475.00

Morana Jovan-Embiricos Buying and Selling Activity at AlloVir

AlloVir Company Overview

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Today's Range

Now: $0.57

$0.56

$0.64

50 Day Range

MA: $0.78

$0.54

$1.01

2 Week Range

Now: $0.57

$0.52

$2.49

Volume

645,131 shs

Average Volume

617,220 shs

Market Capitalization

$65.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75